Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

A quantitative shRNA screen identifies ATP1A1 as a gene that regulates cytotoxicity by aurilide B.

Takase S, Kurokawa R, Arai D, Kanemoto Kanto K, Okino T, Nakao Y, Kushiro T, Yoshida M, Matsumoto K.

Sci Rep. 2017 May 17;7(1):2002. doi: 10.1038/s41598-017-02016-4.

2.

Cofilin-1 and Other ADF/Cofilin Superfamily Members in Human Malignant Cells.

Shishkin S, Eremina L, Pashintseva N, Kovalev L, Kovaleva M.

Int J Mol Sci. 2016 Dec 22;18(1). pii: E10. doi: 10.3390/ijms18010010. Review.

3.

Multiplex shRNA Screening of Germ Cell Development by in Vivo Transfection of Mouse Testis.

Ho NR, Usmani AR, Yin Y, Ma L, Conrad DF.

G3 (Bethesda). 2017 Jan 5;7(1):247-255. doi: 10.1534/g3.116.036087.

4.

RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers.

Sumimoto H, Takano A, Teramoto K, Daigo Y.

PLoS One. 2016 Nov 15;11(11):e0166626. doi: 10.1371/journal.pone.0166626. eCollection 2016.

5.

RNAi screens identify CHD4 as an essential gene in breast cancer growth.

D'Alesio C, Punzi S, Cicalese A, Fornasari L, Furia L, Riva L, Carugo A, Curigliano G, Criscitiello C, Pruneri G, Pelicci PG, Faretta M, Bossi D, Lanfrancone L.

Oncotarget. 2016 Dec 6;7(49):80901-80915. doi: 10.18632/oncotarget.12646.

6.

The mitochondrial translation machinery as a therapeutic target in Myc-driven lymphomas.

D'Andrea A, Gritti I, Nicoli P, Giorgio M, Doni M, Conti A, Bianchi V, Casoli L, Sabò A, Mironov A, Beznoussenko GV, Amati B.

Oncotarget. 2016 Nov 8;7(45):72415-72430. doi: 10.18632/oncotarget.11719.

7.

miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway.

Samaeekia R, Adorno-Cruz V, Bockhorn J, Chang YF, Huang S, Prat A, Ha N, Kibria G, Huo D, Zheng H, Dalton R, Wang Y, Moskalenko GY, Liu H.

Clin Cancer Res. 2017 Feb 15;23(4):1091-1103. doi: 10.1158/1078-0432.CCR-16-0943. Epub 2016 Jul 19.

PMID:
27435395
8.

Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer.

Iskit S, Lieftink C, Halonen P, Shahrabi A, Possik PA, Beijersbergen RL, Peeper DS.

Oncotarget. 2016 Jul 12;7(28):42859-42872. doi: 10.18632/oncotarget.10230.

9.

KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment.

Zeitouni D, Pylayeva-Gupta Y, Der CJ, Bryant KL.

Cancers (Basel). 2016 Apr 18;8(4). pii: E45. doi: 10.3390/cancers8040045. Review.

10.

Isoforms of Melanopsin Mediate Different Behavioral Responses to Light.

Jagannath A, Hughes S, Abdelgany A, Pothecary CA, Di Pretoro S, Pires SS, Vachtsevanos A, Pilorz V, Brown LA, Hossbach M, MacLaren RE, Halford S, Gatti S, Hankins MW, Wood MJ, Foster RG, Peirson SN.

Curr Biol. 2015 Sep 21;25(18):2430-4. doi: 10.1016/j.cub.2015.07.071. Epub 2015 Aug 27.

11.

In Vivo Loss of Function Screening Reveals Carbonic Anhydrase IX as a Key Modulator of Tumor Initiating Potential in Primary Pancreatic Tumors.

Pore N, Jalla S, Liu Z, Higgs B, Sorio C, Scarpa A, Hollingsworth R, Tice DA, Michelotti E.

Neoplasia. 2015 Jun;17(6):473-80. doi: 10.1016/j.neo.2015.05.001.

12.

In vivo RNAi screens: concepts and applications.

Crotty S, Pipkin ME.

Trends Immunol. 2015 May;36(5):315-22. doi: 10.1016/j.it.2015.03.007. Epub 2015 Apr 27. Review.

13.

Actin cytoskeleton regulation of epithelial mesenchymal transition in metastatic cancer cells.

Shankar J, Nabi IR.

PLoS One. 2015 Mar 10;10(3):e0119954. doi: 10.1371/journal.pone.0119954. eCollection 2015. Erratum in: PLoS One. 2015;10(7):e0132759.

14.

Actin and endocytosis in budding yeast.

Goode BL, Eskin JA, Wendland B.

Genetics. 2015 Feb;199(2):315-58. doi: 10.1534/genetics.112.145540. Review.

15.

Forward genetic screens in mice uncover mediators and suppressors of metastatic reactivation.

Gao H, Chakraborty G, Lee-Lim AP, Mavrakis KJ, Wendel HG, Giancotti FG.

Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16532-7. doi: 10.1073/pnas.1403234111. Epub 2014 Nov 5.

16.

Drugging the undruggable RAS: Mission possible?

Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ.

Nat Rev Drug Discov. 2014 Nov;13(11):828-51. doi: 10.1038/nrd4389. Epub 2014 Oct 17. Review.

17.

In Vivo RNAi-Based Screens: Studies in Model Organisms.

Yamamoto-Hino M, Goto S.

Genes (Basel). 2013 Nov 25;4(4):646-65. doi: 10.3390/genes4040646.

18.

Sensitizing protective tumor microenvironments to antibody-mediated therapy.

Pallasch CP, Leskov I, Braun CJ, Vorholt D, Drake A, Soto-Feliciano YM, Bent EH, Schwamb J, Iliopoulou B, Kutsch N, van Rooijen N, Frenzel LP, Wendtner CM, Heukamp L, Kreuzer KA, Hallek M, Chen J, Hemann MT.

Cell. 2014 Jan 30;156(3):590-602. doi: 10.1016/j.cell.2013.12.041.

19.

Stable RNA interference rules for silencing.

Fellmann C, Lowe SW.

Nat Cell Biol. 2014 Jan;16(1):10-8. doi: 10.1038/ncb2895. Review.

20.

Niche-based screening identifies small-molecule inhibitors of leukemia stem cells.

Hartwell KA, Miller PG, Mukherjee S, Kahn AR, Stewart AL, Logan DJ, Negri JM, Duvet M, Järås M, Puram R, Dancik V, Al-Shahrour F, Kindler T, Tothova Z, Chattopadhyay S, Hasaka T, Narayan R, Dai M, Huang C, Shterental S, Chu LP, Haydu JE, Shieh JH, Steensma DP, Munoz B, Bittker JA, Shamji AF, Clemons PA, Tolliday NJ, Carpenter AE, Gilliland DG, Stern AM, Moore MA, Scadden DT, Schreiber SL, Ebert BL, Golub TR.

Nat Chem Biol. 2013 Dec;9(12):840-8. doi: 10.1038/nchembio.1367. Epub 2013 Oct 27.

Supplemental Content

Support Center